tiprankstipranks
Blurbs

Analysts Offer Insights on Technology Companies: Coursera (COUR), Intel (INTC) and Morphic Holding (MORF)

There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Coursera (COURResearch Report), Intel (INTCResearch Report) and Morphic Holding (MORFResearch Report) with bullish sentiments.

Coursera (COUR)

BMO Capital analyst Jeffrey Silber maintained a Buy rating on Coursera today and set a price target of $24.00. The company’s shares closed last Thursday at $17.18.

According to TipRanks.com, Silber is ranked #107 out of 8565 analysts.

Currently, the analyst consensus on Coursera is a Strong Buy with an average price target of $21.80, implying a 26.2% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Intel (INTC)

In a report released today, Cody Acree from Benchmark Co. reiterated a Buy rating on Intel, with a price target of $42.00. The company’s shares closed last Thursday at $32.52.

According to TipRanks.com, Acree is a 5-star analyst with an average return of 18.6% and a 64.3% success rate. Acree covers the Technology sector, focusing on stocks such as Advanced Micro Devices, indie Semiconductor, and Texas Instruments.

Intel has an analyst consensus of Hold, with a price target consensus of $37.31, representing a 13.4% upside. In a report issued on October 25, Raymond James also maintained a Buy rating on the stock with a $40.00 price target.

Morphic Holding (MORF)

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Morphic Holding, with a price target of $52.00. The company’s shares closed last Thursday at $20.28, close to its 52-week low of $19.80.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 6.0% and a 45.9% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Bristol-Myers Squibb.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Morphic Holding with a $64.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COUR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles